



Advancing the Future of IRDs: Opus Genetics Clinical Development Update

Ben Yerxa, PhD
Euretica Innovation Spotlight
September 30, 2026



Disclosures and Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements related to our continued clinical development, clinical results, preclinical data, and future plans for OPGx-BEST1, including the anticipated timing of dosing completion and topline data from Cohort 2 of the OPGx-BEST1 Phase 1/2 clinical trial; the outcome of our ongoing regulatory interactions with the U.S. Food and Drug Administration (the “FDA”) and our expectations regarding the design of, and potential endpoints for, of any pivotal clinical trial of OPGx-BEST1; our expectations regarding the clinical and therapeutic potential of OPGx-BEST1, including with respect to its ability to improve visual function and retinal structure in patients with BEST1-related retinal disease; our estimates of the BEST1 symptomatic patient population in the U.S. and globally; and our expectations regarding our company, its business prospects, and our results of operations. These forward-looking statements are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: our clinical data related to gene therapies for the treatment of inherited retinal diseases is preliminary and related to a relatively small group of patients, and, as a result, data that initially appears promising may be revised, updated, or invalidated at a later data readout and/or may ultimately not be capable of duplication in additional patients; our gene therapy product candidates are based on a novel technology that is difficult to develop and manufacture, which may result in delays and difficulties in obtaining regulatory approval; our planned clinical trials may face substantial delays, result in failure, or provide inconclusive or adverse results that may not satisfy the FDA requirements to further develop our therapeutic products; delays or difficulties associated with patient enrollment in clinical trials may affect our ability to conduct and complete those clinical trials and obtain necessary regulatory approvals; changes in regulatory requirements could result in increased costs or delays in development timelines; we depend heavily on the success of our product pipeline; if we fail to find strategic partners or fail to adequately develop or commercialize our pipeline products, our business will be materially harmed; we have not generated significant revenue from sales of any products and expect to incur losses for the foreseeable future; our future viability is difficult to assess due to our short operating history and our future need for substantial additional capital, access to which could be limited by any adverse developments that affect the financial services markets; we rely on third parties for material aspects of our business, such as conducting our nonclinical and clinical trials and supplying and manufacturing bulk drug substances, which exposes us to certain risks; and those risks and uncertainties described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and our subsequent filings with the U.S. Securities and Exchange Commission (the “SEC”). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect.


Building a Differentiated Gene Therapy Platform

	Preclinical	IND-enabling	Phase 1/2	Phase 3	Approval
OPGx-LCA5 LCA <i>co-funded by FDA OOPD</i>					
OPGx-BEST1 <i>Bestrophinopathies</i>					
OPGx-RDH12 LCA <i>co-funded by Global RDH12 Alliance</i>					
OPGx-MERTK RP <i>co-funded by FFB RD Fund & Abu Dhabi's Healthcare Research and Innovation Fund</i>					
OPGx-RHO adRP <i>co-funded by FFB & NIH</i>					
OPGx-NMNAT1 LCA					
OPGx-CNGB1 RP <i>NIH-funded consortium</i>					
Undisclosed IRD GTx					

All gene therapy programs have the potential to qualify for a Priority Review Voucher

Opus Genetics owns worldwide rights to all gene therapy programs.

adRP, autosomal dominant retinitis pigmentosa; BEST1, bestrophin 1; CNGB1, cyclic nucleotide-gated channel β 1; FDA OOPD, Food and Drug Administration Office of Orphan Products Development; FFB, Foundation Fighting Blindness; GTx, gene therapy; LCA5, Leber congenital amaurosis 5; NIH, National Institutes of Health; RD, retinal degeneration; RDH12, retinol dehydrogenase 12; RHO, rhodopsin; RP, retinitis pigmentosa; MERTK, MER proto-oncogene tyrosine kinase; NMNAT1, nicotinamide mononucleotide adenylyltransferase.

A Newton's cradle with several silver spheres and one red sphere, set against a dark blue background with faint white lines.


OPGx-LCA5



Alan,
LCA5 patient


OPGx-LCA5: Designed to Restore Structure and Function in Photoreceptors

- Lebercilin is a ciliary protein critical for the function of photoreceptor inner and outer segments¹
- In *LCA5* patients, photoreceptor function is severely impaired due to a lack of functioning lebercilin¹
 - However, photoreceptors can survive through the third decade of life, suggestive of a broad window for therapeutic intervention²




- **OPGx-LCA5 is designed to address mutations in the *LCA5* gene, which encodes for the lebercilin protein**
 - Clinically derisked AAV8 vector delivers a functional *LCA5* gene directly to photoreceptor cells
 - Same promoter technology as LUXTRNA®
 - Validated surgical delivery method via subretinal injection

Microperimetry Data Provides Evidence of Increased Sensitivity and Movement of Fixation Toward the Fovea



Adult Participant 01-04



Pediatric Participant 01-06


OPGx-BEST1



Juan,
BEST1 patient

BEST1 Disease Biology

Most Common BEST1 Phenotypes




BVMD



ARB

- Vitelliform material occurs early and is the hallmark of BVMD
- Subretinal fluid occurs late in disease and pools in atrophic areas


STAGE 1 Pre-vitelliform




STAGE 2 Vitelliform




STAGE 3 Pseudohypopyon



STAGE 4 Vitelliruptive




STAGE 5 Atrophy/Fibrosis




Phase 1/2
Cohort 1
Participants

Stages of BVMD

Participant 101-106 (BVMD): Vitelliform Material Reduction Co-localized with Microperimetry Improvements



Lesion reduction consistent with improved function of RPE cells and treatment activity as indicated in microperimetry improvements





THANK
YOU

